MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Thermo Fisher Scientific Retained Earnings 2011-2026 | TMO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59.2 B | 53.1 B | 47.4 B | 41.9 B | 35.4 B | 28.1 B | 22.1 B | 18.7 B | 15.9 B | 13.9 B | 12.1 B | 10.4 B | 8.75 B | 7.7 B | 6.72 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 59.2 B | 6.72 B | 25.4 B |
Quarterly Retained Earnings Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57.4 B | 55.9 B | 54.4 B | 51.4 B | 49.9 B | 48.5 B | 45.9 B | 44.3 B | 43.1 B | 41.9 B | 40.5 B | - | 37.5 B | 35.4 B | 33.9 B | 32.1 B | 30.4 B | 28.1 B | 28.1 B | 28.1 B | 28.1 B | 22.1 B | 22.1 B | 22.1 B | 22.1 B | 18.7 B | 18.7 B | 18.7 B | 18.7 B | 15.9 B | 15.9 B | 15.9 B | 15.9 B | 13.9 B | 13.9 B | 13.9 B | 13.9 B | 12.1 B | 12.1 B | 12.1 B | 12.1 B | 10.4 B | 10.4 B | 10.4 B | 10.4 B | 8.75 B | 8.75 B | 8.75 B | 8.75 B | 7.7 B | 7.7 B | 7.7 B | 7.7 B | 6.72 B | 6.72 B | 6.72 B | 6.72 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 57.4 B | 6.72 B | 22.9 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
348 M | $ 113.95 | -0.77 % | $ 34.6 B |  USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 17.3 | -2.92 % | $ 922 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 16.4 | 0.61 % | $ 176 M |  China |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.24 | -0.52 % | $ 386 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 168.88 | 0.33 % | $ 8.37 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 24.9 | 0.67 % | $ 692 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
|
Biodesix
BDSX
|
-462 M | $ 15.24 | -0.78 % | $ 1.98 B | USA |
 |
Danaher Corporation
DHR
|
46.9 B | $ 191.24 | -0.44 % | $ 136 B | USA |
 |
DexCom
DXCM
|
2.43 B | $ 64.09 | 1.39 % | $ 25 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 16.44 | 0.12 % | $ 497 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Guardant Health
GH
|
-2.99 B | $ 90.19 | 0.59 % | $ 11.3 B | USA |
 |
Anixa Biosciences
ANIX
|
-252 M | $ 2.61 | 0.77 % | $ 84.7 K | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.13 | -2.07 % | $ 4.89 M | USA |
 |
BioNano Genomics
BNGO
|
-720 M | $ 1.13 | -1.7 % | $ 6.15 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 108.32 | -1.18 % | $ 8.93 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.97 | - | $ 8.72 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 127.78 | 0.03 % | $ 20.3 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Celcuity
CELC
|
-449 M | $ 113.83 | -0.35 % | $ 5.32 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 275.15 | 0.21 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 76.09 | 0.26 % | $ 5.14 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 497.15 | 0.23 % | $ 14.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 199.79 | 0.37 % | $ 22.2 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.7 | 0.64 % | $ 435 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-110 M | $ 4.74 | - | $ 3.73 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 8.04 | 0.25 % | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.63 | 0.73 % | $ 2.09 B | USA |
 |
Natera
NTRA
|
-1.94 B | $ 206.6 | 0.84 % | $ 20.3 B | USA |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.38 | -2.82 % | $ 414 M | USA |
 |
Precipio
PRPO
|
-103 M | $ 25.98 | - | $ 41.7 M | USA |
 |
Personalis
PSNL
|
-550 M | $ 6.38 | -3.04 % | $ 378 M | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |